FindTrial
Sign In

The usefulness of immune checkpoint inhibitors among lung cancer patients with driver gene mutants

The usefulness of immune checkpoint inhibitors among lung cancer patients with driver gene mutants - The usefulness of immune checkpoint inhibitors among lung cancer patients with driver gene mutants

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000040789
Enrollment
Unknown
Registered
2020-06-16
Start date
2020-06-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Sponsors

Yokohama City University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who enrolled the phase 2 or 3 clinical trials for the treatment with chemotherapy

Exclusion criteria

Exclusion criteria: Patients who excluded from clinical trials

Design outcomes

Primary

MeasureTime frame
Progression free survival—

Countries

Japan

Contacts

Public ContactNobuaki Kobayashi

Yokohama City University Department of Pulmonogy

nkobayas@yokohama-cu.ac.jp+81453527962

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026